Phototherapy for atopic dermatitis

Rodenbeck, Dorothy L.; Silverberg, Jonathan I.; Silverberg, Nanette B.

doi:10.1016/j.clindermatol.2016.05.011

Cited by 72 publications

(55 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, associated with temperature increases in the southern US, there is an increase in the amount of ambient light levels. Because of the phenomenon of photosensitive AD, our study is not able to distinguish between the effects of solar radiation, seasonality, and temperature. Other possibly atopic‐related diseases may also occur in the summer, such as summer prurigo, frictional lichenoid dermatitis, and nummular dermatitis .…”

Section: Discussionmentioning

confidence: 95%

Atopic dermatitis: the relationship to temperature and seasonality in the United States

Fleischer

2018

Int J Dermatology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 95%

Atopic dermatitis: the relationship to temperature and seasonality in the United States

Fleischer

2018

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…A complete review of the published literature on this topic, including a total of 428 studies regarding the efficacy and safety of phototherapy [30], as well as an up-to-date review on 19 randomized controlled trials (including 905 participants) [31] confirmed that medium-dose UVA1 and NB-UVB phototherapies are the most effective and safe modalities for adult AD treatment as also observed in various randomized controlled trials and other studies [24, 32–37]. As a rule, phototherapy is not indicated in the acute stage of AD (except UVA1, which is also effective in managing AD flares) [38–40], but is more apt to treat chronic, pruritic, lichenified forms [24, 35], and should not be prescribed in those patients who experience a worsening of their dermatosis during sun exposure as in the case of other common chronic inflammatory diseases such as psoriasis [41]. In general, NB-UVB has been indicated for chronic-moderate forms of AD and is currently preferred to broadband UV because it is less erythemogenic; a recent study reported that the combination with UVA did not show any further benefits [42].…”

Section: Methodsmentioning

confidence: 97%

“…Nevertheless, it is considered a safe and well-tolerated therapeutic approach, it is limited by the inconvenience and possible adverse events, including limited access to in-office treatment, difficulty adhering to a thrice-weekly schedule, erythema, photodamage, actinic keratosis, blistering and herpes virus reactivation. On the other hand, long-term side effects such as premature photoaging and carcinogenesis have not been excluded [35, 37]. Safe use of NB-UVB and medium-dose UVA1 has been well documented, and it was cited as the most commonly used wave length and modality of light-based therapy for AD [30, 31, 34, 45].…”

Section: Methodsmentioning

confidence: 99%

Systemic Treatment of Adult Atopic Dermatitis: A Review

Megna

Napolitano

Patruno

et al. 2016

Dermatol Ther (Heidelb)

133

109

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a common chronic inflammatory skin disease that predominantly affects children. However, it can persist in adulthood and/or start at older ages. Due to its chronic nature and frequently occurring relapses, AD has a substantial effect on patients' quality of life, often requiring long-term systemic treatment, especially in adult patients, who are more frequently refractory to adequate topical treatment with mid- to high-potent corticosteroids and/or calcineurin inhibitors. Therefore, treatment with systemic therapies is often needed to take control of the disease, prevent exacerbations and improve quality of life. However, data regarding systemic treatment effectiveness and long-term safety in adult patients with AD are insufficient. Indeed, standardized international guidelines are lacking, and the treatment approach widely differs among diverse countries. This review focuses on the use of systemic treatments in adult AD patients analyzing published literature.

show abstract

“…The following phototherapy sources are widely used in the treatment of AD: Narrow Band‐ Ultraviolet B (NB‐UVB) emitting a maximum peak at 311–313 nm for chronic and moderate AD. Less frequently, UVA1 (340–400 nm) for more severe phase (Rodenbeck, Silverberg, & Silverberg, ). …”

Section: Therapeutic Approachesmentioning

confidence: 99%

“…• Less frequently, UVA1 (340-400 nm) for more severe phase (Rodenbeck, Silverberg, & Silverberg, 2016).…”

Section: Phototherapymentioning

confidence: 99%

Italian guidelines for therapy of atopic dermatitis—Adapted from consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis)

Damiani

Calzavara‐Pinton

Stingeni

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Atopic dermatitis (AD) therapeutic approach calls for a long‐term treatment. Treatment options for AD have recently undergone a revolutionary change by the introduction of the first biologic drug. Availability in daily practice of the last version of international AD guidelines, taking peculiarities of the country into account, can contribute to good clinical practice in Italy. To adapt European Dermatology Forum (EDF) guidelines for AD to the Italian medical–legal context, the EDF guidelines were assessed independently by two independent Italian renowned experts in the field and further integrated with articles published and systematically reviewed before May 2019. The first draft was collegially corrected and updated by the members of the SIDEMAST, ADOI, and SIDAPA. Recommendation levels (A; B; C; D) were graded based on the evidence levels (1–4). The adapted guidelines presented here focus on topical and systemic therapies in AD patients, both children and adults. As opposed to previous Italian guidelines, they include indications about biologics. New relevant evidence available from very recent literature and peculiarities of the Italian medical and legal context have been integrated in the revision process. If compared to general guidelines for AD not adapted to a specific national and cultural context, a revision for specific Italian needs is now available: It comprises the option of implementing the new biologic treatments and is likely to provide an important contribution to the improvement of clinical practice in Italy. Cooperation between patients, dermatologists, allergologists, and pediatricians remains mandatory in AD management. The authors of the present revision recommend an update of the Italian guidelines to be performed at least every second year.

show abstract

Phototherapy for atopic dermatitis

Cited by 72 publications

References 70 publications

Atopic dermatitis: the relationship to temperature and seasonality in the United States

Atopic dermatitis: the relationship to temperature and seasonality in the United States

Systemic Treatment of Adult Atopic Dermatitis: A Review

Italian guidelines for therapy of atopic dermatitis—Adapted from consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis)

Contact Info

Product

Resources

About